Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB)

Historical Holders from Q3 2018 to Q3 2025

Symbol
YMAB
CUSIP
984241109
Type / Class
Equity / Common stock, par value $0.0001 per share
Shares outstanding
45.1M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
27.9M
Holdings value
$126M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
96
Number of buys
41
Number of sells
-54
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Beryl Capital Management LLC 9% $18.4M 4.09M Beryl Capital Management LLC Aug 5, 2025
ACORN BIOVENTURES, L.P. 6.2% -11.4% $23.8M -$2.56M 2.8M -9.69% Anders Hove Aug 19, 2025
GLAZER CAPITAL, LLC 5.84% $22.6M 2.65M Glazer Capital, LLC Aug 8, 2025
Caligan Partners LP 5.2% $10.9M 2.34M Caligan Partners LP Mar 31, 2025

Institutional Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 0 $0 -$48.5K 0
2025 Q2 27.9M $126M -$3.99M $4.51 96
2025 Q1 28.8M $128M -$6.93M $4.43 102
2024 Q4 28.8M $225M -$943K $7.83 111
2024 Q3 25.7M $339M +$17.3M $13.15 105
2024 Q2 24.4M $294M +$14.9M $12.08 95
2024 Q1 23M $374M +$50.2M $16.26 94
2023 Q4 15.6K $106K -$258K $6.82 1
2023 Q3 19.7M $107M -$1.39M $5.45 98
2023 Q2 19.5M $132M +$4.78M $6.79 94
2023 Q1 19M $95.4M -$1.13M $5.01 83
2022 Q4 19.2M $93.6M -$55.2M $4.88 88
2022 Q3 23.1M $333M -$15.4M $14.42 90
2022 Q2 24.2M $366M -$5.52M $15.13 87
2022 Q1 21.9M $260M -$16.6M $11.88 83
2021 Q4 25.4M $411M -$18.3M $16.21 88
2021 Q3 26.2M $748M -$509K $28.54 95
2021 Q2 26.1M $886M -$1.16M $33.80 98
2021 Q1 26.3M $796M +$113M $30.24 115
2020 Q4 22M $1.09B +$38.1M $49.51 111
2020 Q3 21.2M $814M +$2.71M $38.39 102
2020 Q2 20.8M $898M +$48.7M $43.20 106
2020 Q1 20M $520M +$15.5M $26.10 77
2019 Q4 19.4M $606M +$185M $31.25 80
2019 Q3 13.1M $341M +$56.1M $26.06 63
2019 Q2 11M $251M +$54.3M $22.87 58
2019 Q1 8.47M $222M -$3.28M $26.21 43
2018 Q4 8.69M $176M +$18.7M $20.34 42
2018 Q3 7.73M $204M +$204M $26.56 38